Name: Scriptaid
Price: 294.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Scriptaid, identified by a high-throughput transcriptional screening, is a novel histone deacetylase (HDAC) with specific potency towards class I HDACs (50% inhibition concentration IC50 values of 0.6 μM for HDAC1 and HDAC3 and 1 μM for HDAC8). Scriptaid shares a similar chemical structure with several others hydroxamic acid-containing HDAC inhibitors (such as TSA and nullscript), which consists of a hydroxamic acid group, an aliphatic chain and an aromatic cap at the other end. Scriptaid has the potential to be used for the treatment of glioblastoma multiforme (GBM), one of the most challenging solid cancers to treat, for its ability to induce apoptosis in glioblastoma cells.
- Properties
  - Alternative Name
    
    6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
    
    CAS Number
    
    287383-59-9
    
    Molecular Formula
    
    C18H18N2O4
    
    Molecular Weight
    
    326.35
    
    Appearance
    
    A solid
    
    Purity
    
    99.49%
    
    Solubility
    
    insoluble in H2O; ≥13.1 mg/mL in DMSO; ≥3.17 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Ballante F, Reddy DR, et al. "Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy." Bioorg Med Chem. 2017 Apr 1;25(7):2105-2132. PMID:28259528

Scriptaid

Scriptaid

Background

We Also Recommend

MLN8237 (Alisertib)

Resminostat (RAS2410)

Sodium Phenylbutyrate